You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 9,879,267

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,879,267

Title:	Genetic variations associated with drug resistance
Abstract:	Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.
Inventor(s):	Lackner; Mark (South San Francisco, CA), Amler; Lukas C. (Foster City, CA), Cavet; Guy (Burlingame, CA), O\'Brien; Carol (Pacifica, CA), Pandita; Ajay (Redwood City, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA)
Application Number:	12/922,420
Patent Claims:	1. A method of treating breast cancer, comprising (a) determining, in a tissue sample obtained from a human patient with HER2-positive breast cancer who had shown prior progression on HER2-directed therapy, a copy number of an ABCC3 (ATP-Binding Cassette, Sub-Family C, Member 3) gene or an ABCC3 gene amplification value, relative to an amplification value of a centromere 17 (CEP17) gene in the same tissue sample, by fluorescence in situ hybridization (FISH), and (b) administering to the patient whose breast cancer is characterized by an ABCC3 gene copy number of less than 3 or an ABCC3 gene amplification value of less than 1.8 relative to an amplification value of a CEP17 gene an effective amount of a conjugate of trastuzumab and N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine (DM1), or a conjugate of trastuzumab and monomethyl auristatin E (MMAE). 2. The method of claim 1, wherein said conjugate is trastuzumab-N-succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (MCC)-DM1 (T-DM1).

Details for Patent 9,879,267

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2039-02-26
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019	⤷ Try a Trial	2039-02-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.